Persistent parvovirus B19 infection resulting in red cell aplasia after allogeneic hematopoietic stem cell transplantation.
Persistent parvovirus B19 (PVB) infection has been reported sporadically in immunocompromised patients including hematopoietic stem cell and solid organ transplant recipients. However, the pathogenesis of persistent infection has yet to be fully elucidated. We report here a patient with multiple myeloma developing red cell aplasia during the hematopoietic recovery after allogeneic hematopoietic stem cell transplantation (HSCT) caused by PVB. The patient had already had PVB viremia before transplantation and remained asymptomatic. The route of PVB transmission was considered to be direct contact with the patient's family member with primary PVB infection 1 month before transplantation. Treatment with intravenous immunoglobulin resulted in prompt resolution of anemia. These findings suggest that monitoring of PVB DNA is recommended for patients undergoing HSCT and having contact with individuals with documented PVB infection, even if they are asymptomatic.
['Koda|Y|Y|', 'Mori|T|T|', 'Kato|J|J|', 'Kohashi|S|S|', 'Kikuchi|T|T|', 'Mitsuhashi|T|T|', 'Murata|M|M|', 'Uemura|T|T|', 'Handa|M|M|', 'Okamoto|S|S|']
D000328:Adult D016731:Erythema Infectiosum D018380:Hematopoietic Stem Cell Transplantation D006801:Humans D016756:Immunoglobulins, Intravenous D007155:Immunologic Factors D008297:Male D009101:Multiple Myeloma D016732:Parvovirus B19, Human D012010:Red-Cell Aplasia, Pure
parvovirus B19 red cell aplasia allogeneic hematopoietic stem cell transplantation persistent infection multiple myeloma